Rapport Therapeutics, Inc. Common Stock (RAPP) NASDAQ

25.69

-0.0899(-0.35%)

Updated at October 16 11:45AM

Currency In NaN

Rapport Therapeutics, Inc. Common Stock

Address

1325 Boylston Street

Boston, DE

United States of America

Phone

N/A

Sector

Healthcare

Industry

Biotechnology

Employees

69

First IPO Date

N/A

Key Executives

NameTitlePayYear Born
Mr. Abraham N. Ceesay M.B.A.Chief Executive Officer, President, Treasurer & Director891,2831978
Dr. Steven M. Paul M.D.Founder & Independent Chairman28,7951951
Ms. Cheryl GaultChief Operating Officer281,1101980
Dr. Troy A. IgnelziChief Financial Officer675,5361968
Mr. Swamy Yeleswaram Ph.D.Chief Development Officer01964
Dr. Arnold R. Gammaitoni Pharm.D.Senior Vice President of Medical Affairs01967
Ms. Kathleen A. WilkinsonChief People Officer01972
Mr. David Bredt M.D., Ph.D.Founder & Chief Scientific Officer01966
Ms. Karina ChmielewskiChief Information Officer & Head of Operations0N/A
Ms. Julie DiCarloHead of Communications & Investor Relations0N/A

Description

Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. Its lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. The company also develops RAP-199, a TARPy8 targeted molecule with differentiated chemical and pharmacokinetic properties; and nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and a9a10 nAChR for the treatment of hearing disorders. The company was formerly known as Precision Neuroscience NewCo, Inc. and changed its name to Rapport Therapeutics, Inc. in October 2022. Rapport Therapeutics, Inc. was incorporated in 2022 and is based in Boston, Massachusetts.